Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
Launched by KECIOREN EDUCATION AND TRAINING HOSPITAL · Aug 12, 2008
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
Context: Respiratory infections are the major cause of wheezing attacks in children with recurrent wheezing or asthma in preschool age. OM-85 BV is an bacteria lysate which has been proven to prevent respiratory infections about 40 percent in children.
Objective: To determine if using OM-85 BV diminish the number and duration of the respiratory infections and respiratory infection related wheezing attacks,beta-2 agonist and steroid use, and number and duration of hospitalizations in children with recurrent wheezing and asthma. And also to determine if OM-85 BV has any effect on serum cytok...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children with recurrent wheezing who had at least 3 wheezing attacks in the last 6 months
- • Children with asthma who had at least 3 wheezing attacks in the last 6 months
- Exclusion Criteria:
- • Chronic lung disease
- • Immun deficiency
- • Malabsorption
- • Anatomic abnormalities of the respiratory tract
- • Gastroesophageal reflux disease
About Kecioren Education And Training Hospital
Kecioren Education and Training Hospital is a leading healthcare institution dedicated to providing high-quality medical care and advancing clinical research. With a focus on education and professional development, the hospital serves as a training ground for healthcare professionals while actively engaging in innovative clinical trials. By fostering a collaborative environment between clinicians and researchers, Kecioren aims to enhance patient outcomes and contribute to the advancement of medical science through rigorous and ethical research practices. The hospital is committed to improving healthcare standards and addressing pressing health challenges in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Kec.Oren, Turkey
Ankara, Keçiören, Turkey
Patients applied
Trial Officials
C H RAZI, MD
Study Director
Kecioren Education and Training Hospital
C H Razi, MD
Principal Investigator
Kecioren Education and Training Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials